Business
BioSpectrum Asia
UK and Singapore launch new regulatory innovation corridor to fast-track health technologies
As part of this first-of-its-kind partnership between the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore's Health Sciences Authority (HSA), companies will have a coordinated fast track pathway to engage both regulators at the same time.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Zydus Lifesciences partners with Myriad Genetics to launch cancer-risk assessment diagnostic tests in India.
India-based Zydus Lifesciences has signed an agreement with US-based Myriad Genetics, a leader in molecular diagnostic testing and precision medicine.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Korea steps up pandemic response with $18.9 M investment in CEPI
The Republic of Korea has announced new $18.9 million support to bolster national and global efforts to protect against the next deadly pandemic and boost international health security.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Belgium and WHO sign new agreement to boost global health accessibility
The World Health Organization (WHO) has announced a new €8 million, four-year contribution from the Government of Belgium to accelerate global equitable access to essential health products and technologies.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Pharmacopoeia Commission of India inks 3 MoUs with Nagaland
The Pharmacopoeia Commission of India (IPC), an autonomous institute under the Ministry of Health and Family Welfare, Government of India, has signed three Memorandums of Understanding (MoUs) with Nagaland Medical Council, Nagaland State Drug Control Administration (NSDCA), Department of Health and Family Welfare, Nagaland and State Pharmacy Council, Government of Nagaland, a northeastern state of India.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
UK to prioritise medical graduates for training places
The UK government has put an offer to the British Medical Association (BMA) that would put in place emergency legislation for UK and Republic of Ireland medical graduates and doctors who have worked in the National Health Service (NHS) for a significant period of time to be prioritised for specialty training and tackling bottlenecks through an overhaul of recruitment for medical training.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Precious Medical Group invests RM500 M for advanced cancer care infrastructure in Malaysia
Singapore-based healthcare provider Precious Medical Group has announced the launch of the Tunku Laksamana Johor Cancer Centre and Hospital, a landmark RM500 million development featuring state-of-the-art diagnostic and treatment facilities.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Insilico Medicine, TaiGen collaborate for AIdriven PHD inhibitor for CKD-related anaemia
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company headquartered in Hong Kong, and Taiwan's TaiGen Biotechnology, a listed discoverybased and market-focused pharmaceutical company, as well as TaiGen Biopharmaceuticals, its wholly-owned Beijing subsidiary, have announced an exclusive pipeline out-licensing collaboration.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
WHO launches new cancer control planning course
In support of cancer control efforts in countries around the world, the WHO Academy has launched a course on National Cancer Control Planning for Programme Managers.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
The Future of mRNA Is Being Built in APAC
Beyond scientific advancement, mRNA represents a strategic opportunity shaped by policy stability, public investment and regional collaboration. Across APAC, governments are increasingly recognising that supportive regulatory frameworks and long-term funding can serve as powerful competitive advantages, attracting global capital and talent.
10 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
US FDA launches novel Digital Health Pilot to expand access to chronic disease technologies
The US Food and Drug Administration (FDA) has announced the TechnologyEnabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot, a voluntary pilot designed to promote access to certain digital health devices while safeguarding patient safety.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
University of Oxford launches world's first Phase II Nipah virus vaccine trial
The University of Oxford has launched the world's first Phase II clinical trial of a Nipah virus vaccine candidate.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
ASIA'S NEW GLOBAL PLAY IN PHARMA INNOVATION
The beginning of the new year has brought two notable developments from Asia's pharmaceutical landscape—one involving a government regulator and the other a private pharmaceutical major. While distinct in nature, both moves share a common strategic objective: stepping beyond regional boundaries to accelerate innovation and improve patient access to breakthrough therapies. One looks westward to Europe, the other to the United States.
2 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
CSL opens cell-based influenza vaccine and antivenom manufacturing facility in Melbourne
Australia's onshore vaccine manufacturing capabilities took a leap forward as Mark Butler MP, Minister for Health, Disability and Ageing, opened CSL Seqirus' state-of-the-art cell-based influenza vaccine and antivenom manufacturing facility in Melbourne.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Cambodia introduces lifesaving rotavirus vaccine nationwide
The Ministry of Health of the Kingdom of Cambodia has announced the nationwide introduction of the rotavirus vaccine into the National Immunisation Schedule, marking a significant milestone in protecting infants and young children from one of the leading causes of severe diarrhoea and child mortality.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
D3 Bio secures $108 M to advance global clinical programmes
D3 Bio, a global clinical-stage biotechnology company from China focused on the discovery and development of innovative oncology therapeutics, has announced the completion of a $108 million Series B financing round.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Rhinocare Korea accelerates global expansion with Singapore joint venture
Rhinocare Korea, a medtech innovator specialising in drug-free respiratory care, has announced plans to establish a joint venture (JV) in Singapore as part of its strategy to expand across Asia-Pacific, Europe, and North America.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Glenmark bags multi-regional rights of Hansoh Pharma's oncology drug for $1 B
Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of India-based Glenmark Pharmaceuticals, has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co., for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC).
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
mRNA landscape in Japan
Japan's mRNA landscape is steadily evolving, shaped by domestic investment, active regulatory engagement, and growing alignment across industry, academia, and government to support both near-term scale-up and longer-term innovation.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Immutep inks oncology deal worth $349.5 M with Dr. Reddy's Laboratories
Australia-based Immutep Limited and Dr. Reddy's Laboratories, based in India, have announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy's Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Galux joins hands with Boehringer Ingelheim to advance AI-driven protein design
Galux, a South Korean biotech startup pioneering AI-driven protein therapeutics discovery, has signed a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence (AI) in precision protein design for therapeutic development.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
ADEL signs $1.04 B deal with Sanofi for novel Alzheimer's therapy
ADEL, Inc., a South Korea-based biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, has entered into an exclusive worldwide license agreement with Sanofi, a multinational healthcare company, for the development and commercialisation of ADEL-Yo1, a potential first-in-class antibody therapy for Alzheimer's disease, and related backup compounds.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
SAI Parenterals acquires Noumed Pharma for Rs 125 Cr
SAI Parenterals Limited (SPL), an India-based pharmaceutical formulation company, has announced the acquisition of a 74.6 per cent controlling stake in Noumed Pharmaceuticals, an Adelaidebased pharmaceutical company, for an aggregate sum of Rs 125 crore.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
GHIT invests $460,000 for development of Mpox detection test prototype
Japan-based Global Health Innovative Technology (GHIT) Fund has announced an investment of approximately JPY 70 million ($460,000) for the development of a prototype detection test for mpox (monkeypox).
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
UST and IIT-M sign MoU to accelerate deep tech startups in healthcare and life sciences
UST, a leading AI and technology transformation solutions company, has signed a Memorandum of Understanding (MoU) with the IIT Madras Incubation Cell (IITMIC), India's premier deep tech startup hub anchored at IIT-Madras, to foster innovation, entrepreneurship, and research-driven solutions in the healthcare and life sciences sector.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Lunit partners with Daiichi Sankyo to advance Aldriven oncology research
South Korea-based Lunit, a leading provider of AI for cancer diagnostics and precision oncology, has announced a collaboration with Japanese pharma firm Daiichi Sankyo that aims to accelerate biomarker discovery and optimise translational research by integrating multiple AI-powered Lunit SCOPE digital pathology products across two oncology pipeline programmes.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
New Zealand maintains comprehensive respiratory surveillance system
The Ministry of Health, in consultation with partners the National Public Health Service and PHF Science, has decided to not renew its contract for FluTracking New Zealand because New Zealand has other surveillance tools for respiratory illnesses that provide similar information.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Respiree gets HSA's approval for 1Bio AI-Acute toolbox to support healthcare
Singapore-based health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio AI-Acute toolbox as a Class B software-as-a-medical device (SaMD).
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Seeing Opportunity in Ophthalmology
Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.
6 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Fapon, Bio Farma partner to advance IVD localisation and innovation in Indonesia
PT Fapon Bioindustries Indonesia and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) have signed a cooperation agreement.
1 min |